Bayer defies critics with $62 billion Monsanto offer


FRANKFURT German drugs and stand chemicals organisation Bayer AG has offering to buy U.S. seeds association Monsanto for $62 billion in cash, defying some of a possess shareholders in a bid to squeeze a tip mark in a fast-consolidating plantation reserve industry.

Monsanto Co’s batch finished trade adult 4.4 percent during $106 on a New York Stock Exchange on Monday, good next Bayer’s $122 per share money offer price, in a pointer that it faces a tough charge convincing a St. Louis-based association to pointer off on a deal.

Monsanto has pronounced it would examination a proposal. Some analysts have suggested Bayer competence still have to compensate more.

“The cost that has now been disclosed is during a tip extent and it is usually about economical. Should it arise further, that is to be assumed, a takeover will turn increasingly unattractive,” pronounced Markus Manns, a comment manager during Union Investment, Bayer’s 14th biggest investor

Other Bayer shareholders have also responded coldly to a company’s pursuit, cursed by one Bayer financier as “arrogant empire-building” when news of a offer emerged final week.

The unsolicited offer would be a largest all-cash takeover on record, according to Thomson Reuters data, usually brazen of InBev’s $60.4 billion offer for Anheuser-Busch in Jun 2008.

The pierce would also obscure a designed mixed of peers Dow Chemical and DuPont’s cultivation units and comes usually 3 weeks after Werner Baumann took over as Bayer CEO.

Giving sum for a initial time, Bayer pronounced on Monday it would offer $122 per share, a 37 percent reward to Monsanto’s batch cost before rumors of a bid surfaced.

“We entirely design a certain answer of a Monsanto house of directors,” Baumann told reporters on a discussion call, describing critique from some investors as “an untaught greeting in a media” when understanding terms were not nonetheless known, and driven by an component of surprise.

Monsanto, that pronounced final week it had a perceived an proceed from Bayer though gave no details, declined to comment.

Seven of Monsanto’s tip 20 investors declined to criticism about Bayer’s offer when contacted by Reuters. Others could not be immediately reached for comment.

Antitrust experts see an overlie in a seeds business, quite in soybeans, string and canola. Bayer’s LibertyLink line of weed killers, and crops that are resistant to it, are an critical choice for farmers pang from weeds that have grown resistant to Monsanto’s Roundup herbicide.

Shares of Bayer, that had already depressed 14 percent given rumors of a bid emerged final week, finished trade down 5.7 percent on Monday to a new 2-1/2 year low of 84.42 euros.


Global agrochemicals companies are racing to consolidate, partly in response to a dump in commodity prices that has strike plantation incomes, and also due to a flourishing joining between seeds and pesticides markets.

ChemChina is shopping Switzerland’s Syngenta for $43 billion after Syngenta deserted a bid from Monsanto, while Dow and DuPont are forging a $130 billion business.

With German opposition BASF SE also looking into a probable tie-up with Monsanto, Bayer has changed to equivocate being left behind.

Baumann deserted suggestions from some investors that Bayer should instead try to forge a corner try with Monsanto, observant this would have taxation disadvantages.

Monsanto approached Bayer in Mar to demonstrate seductiveness in a stand scholarship unit, Reuters reported during a time. Among a possibilities discussed were an undisguised merger of a stand scholarship section and a corner venture, or other form of partnership between a dual companies.

Sources tighten to a matter have pronounced BASF is doubtful to start a behest fight with Bayer. BASF declined to criticism on Monday.

But analysts contend Bayer competence still have to compensate some-more to convince Monsanto and a shareholders to sell up.

That could be a problem, with some observant Bayer’s proposal, during 15.8 times Monsanto’s gain before interest, tax, debasement and amortization (EBITDA) for a year finished Feb. 29, is already a widen for a German company.

Berenberg researcher John Klein pronounced Monsanto and a shareholders were expected to disagree that formed on 2017 EBITDA expectations, a bid would paint a mixed of usually 14 times, compared with a scarcely 16 times ChemChina concluded to compensate for Syngenta When pulpy by analysts either Bayer competence pacify a bid, Baumann pronounced a offer reflected Monsanto’s value.

“We are putting brazen a very, really full price,” he said.


Bayer pronounced it would financial a bid with a mixed of debt and equity, essentially a share sale to existent investors. Equity would comment for about a entertain of a understanding value.

Equinet researcher Marietta Miemietz, who has a ‘buy’ rating on Bayer stock, pronounced a additional debt seemed docile though could extent Bayer’s ability to deposit in a medical business, that some analysts consider needs a boost to a drugs pipeline.

Baumann pronounced Bayer would continue to rise a medical arm, that includes cadence impediment tablet Xarelto and aspirin, a painkiller it invented some-more than a century ago.

“We are not feeding Peter by starving Paul here,” he said, adding no item sales were designed to assistance compensate for a deal.

Bayer also foresee synergies from a understanding with Monsanto would boost annual gain by around $1.5 billion after 3 years, and additional destiny advantages from integrated product offerings – a anxiety to a pull to mix a growth and sale of seeds and stand insurance chemicals.

Berenberg analysts, who have a ‘buy’ rating on Bayer shares, described a synergies guess as “very ambitious”.

(Additional stating by Maria Sheahan, Patricia Weiss, Karl Plume and Michael Flaherty; Editing by Edwina Gibbs, Mark Potter and Bernard Orr)


About Author

Leave A Reply